WallachBeth Capital Completes $5.7M Joint Underwritten Public Offering for Lixte Biotechnology Holdings

12/1/20

WallachBeth Capital, a leading provider of capital markets and institutional execution services, announced the completion of a joint underwritten public offering of 1,200,000 shares for Lixte Biotechnology Holdings, Inc. (NASDAQ: Common stock – LIXT; Warrants – LIXTW) at an offering price of $4.75 per unit for total gross proceeds of $5.7 million, before deducting underwriting discounts and commissions and other estimated offering expenses and before any exercise of the underwriters' overallotment option. Each unit consists of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $5.70 per share. In addition, Lixte has granted the underwriters a 45-day option to purchase up to 180,000 additional shares of the Company's common stock and/or up to 180,000 additional warrants to purchase shares of the Company's common stock, or any combination thereof, to cover overallotments, if any. The shares and warrants began trading on The NASDAQ Capital Market on Wednesday, November 25, 2020, under the symbols "LIXT" and "LIXTW", respectively.

WallachBeth Capital, LLC acted as book-running manager for the offering.

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with cancer and other serious common diseases and then designs novel compounds to attack those targets. Lixte's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint. The Company believes the phosphatase inhibitors have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. Additional information about Lixte Biotechnology Holdings, Inc. is available at www.lixte.com.

About WallachBeth Capital LLC

WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community, connecting corporate clients with leading institutions, creating value for both issuers and investors. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, and private transactions. WallachBeth Capital is a leading provider of institutional execution services, offering clients a full spectrum of solutions to help them navigate increasingly complex markets. The firm's website is located at www.wallachbeth.com.

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.